Stifel Financial’s KALA BIO KALA Stock Holding History

Stifel Financial’s Portfolio KALA Stock Details KALA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-4	Closed	-$69K	–	3347
2021 Q1	$69K	Buy	+4	New	+$78.1K	﹤0.01%	3146

Other funds holding KALA

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Caxton Corporation Princeton, New Jersey $4.02M AUM 256.08% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Stifel Financial's KALA Position: Q2 2021 in Review

Stifel Financial sold out of KALA BIO (KALA) in Q2 2021, closing a stake of 4 shares — an estimated $69K sold.

Stifel Financial first reported a position in KALA in Q1 2021 and held it in 1 quarter. The position peaked at $69K in Q1 2021. 97 funds tracked by Wall St. Rank hold KALA as of Q2 2021.

Stifel Financial reported no remaining KALA BIO position as of Q2 2021 after selling out during the quarter.
Stifel Financial sold 4 KALA BIO shares in Q2 2021, an estimated $69K.
Stifel Financial first reported a position in KALA BIO in Q1 2021 and held it in 1 quarter.
Stifel Financial's KALA BIO position peaked at $69K in Q1 2021.
97 funds tracked by Wall St. Rank held KALA BIO as of Q2 2021.

Based on Stifel Financial's 13F filing for Q2 2021, filed 13 Aug 2021.